Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 19, 2026.

Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer

Seong-Keun Yoo, Young Shin Song, Eun Kyung Lee and 13 more (opens in a new tab)

Nature Communications · 2019 · CC BY

doi:10.1038/s41467-019-10680-5 (opens in a new tab)

Abstract

Anaplastic thyroid cancer (ATC) and advanced differentiated thyroid cancers (DTCs) show fatal outcomes, unlike DTCs. Here, we demonstrate mutational landscape of 27 ATCs and 86 advanced DTCs by massively-parallel DNA sequencing, and transcriptome of 13 ATCs and 12 advanced DTCs were profiled by RNA sequencing. TERT , AKT1 , PIK3CA , and EIF1AX were frequently co-mutated with driver genes ( BRAF V600E and RAS ) in advanced DTCs as well as ATC, but tumor suppressors (e.g., TP53 and CDKN2A ) were predominantly altered in ATC. CDKN2A loss was significantly associated with poor disease-specific survival in patients with ATC or advanced DTCs, and up-regulation of CD274 (PD-L1) and PDCD1LG2 (PD-L2). Transcriptome analysis revealed a fourth molecular subtype of thyroid cancer (TC), ATC-like, which hardly reflects the molecular signatures in DTC. Furthermore, the activation of JAK-STAT signaling pathway could be a potential druggable target in RAS -positive ATC. Our findings provide insights for precision medicine in patients with advanced TCs.

References 72

  1. 1.

    Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690.

    Not in our library10.1016/j.cell.2014.09.050 (opens in a new tab)

  2. 2.
    Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers · 2016
    No notice
  3. 3.

    Keutgen XM, Sadowski SM, Kebebew E. Management of anaplastic thyroid cancer. Gland Surg. 2015;4:44-51.

    Not in our library10.3978/j.issn.2227-684x.2014.12.02 (opens in a new tab)

  4. 4.

    Molinaro E, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 2017;13:644-660.

    Not in our library10.1038/nrendo.2017.76 (opens in a new tab)

  5. 5.

    D’Avanzo A, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer. 2004;100:1123-1129.

    Not in our library10.1002/cncr.20081 (opens in a new tab)

  6. 6.

    Durante C, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 2006;91:2892-2899.

    Not in our library10.1210/jc.2005-2838 (opens in a new tab)

  7. 7.

    Ibrahimpasic T, et al. Outcomes in patients with poorly differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 2014;99:1245-1252.

    Not in our library10.1210/jc.2013-3842 (opens in a new tab)

  8. 8.

    Landa I, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 2016;126:1052-1066.

    Not in our library10.1172/jci85271 (opens in a new tab)

  9. 9.

    Pozdeyev Nikita, Gay Laurie M., Sokol Ethan S., Hartmaier Ryan, Deaver Kelsi E., Davis Stephanie, French Jena D., Borre Pierre Vanden, LaBarbera Daniel V., Tan Aik-Choon, Schweppe Rebecca E., Fishbein Lauren, Ross Jeffrey S., Haugen Bryan R., Bowles Daniel W. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clinical Cancer Research. 2018;24(13):3059-3068.

    Not in our library10.1158/1078-0432.ccr-18-0373 (opens in a new tab)

  10. 10.

    Cancer Genome Atlas Research N.. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519-525.

    Not in our library10.1038/nature11404 (opens in a new tab)

  11. 11.

    Alaei-Mahabadi B, Bhadury J, Karlsson JW, Nilsson JA, Larsson E. Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers. Proc. Natl Acad. Sci. USA. 2016;113:13768-13773.

    Not in our library10.1073/pnas.1606220113 (opens in a new tab)

  12. 12.

    Jung SH, et al. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma. Oncotarget. 2016;7:69638-69648.

    Not in our library10.18632/oncotarget.11922 (opens in a new tab)

  13. 13.

    Ye L, et al. The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing. Nat. Commun. 2017;8:15533.

    Not in our library10.1038/ncomms15533 (opens in a new tab)

  14. 14.

    Graubert TA, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 2011;44:53-57.

    Not in our library10.1038/ng.1031 (opens in a new tab)

  15. 15.

    Ju YS, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436-445.

    Not in our library10.1101/gr.133645.111 (opens in a new tab)

  16. 16.

    Taylor PN, et al. Whole-genome sequence-based analysis of thyroid function. Nat. Commun. 2015;6:5681.

    Not in our library10.1038/ncomms6681 (opens in a new tab)

  17. 17.

    Hayashi M, et al. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3’,5’-cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 1998;250:751-756.

    Not in our library10.1006/bbrc.1998.9379 (opens in a new tab)

  18. 18.

    Valentijn LJ, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat. Genet. 2015;47:1411-1414.

    Not in our library10.1038/ng.3438 (opens in a new tab)

  19. 19.

    Peifer M, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700-704.

    Not in our library10.1038/nature14980 (opens in a new tab)

  20. 20.

    Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.

    Not in our library10.1038/nature12477 (opens in a new tab)

  21. 21.

    Rubinstein JC, et al. Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma. BMC Cancer. 2016;16:646.

    Not in our library10.1186/s12885-016-2665-7 (opens in a new tab)

  22. 22.

    Ogata H, et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999;27:29-34.

    Not in our library10.1093/nar/27.1.29 (opens in a new tab)

  23. 23.

    Kofler NM, et al. Notch signaling in developmental and tumor angiogenesis. Genes Cancer. 2011;2:1106-1116.

    Not in our library10.1177/1947601911423030 (opens in a new tab)

  24. 24.

    Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2012;2:a006502.

    Not in our library10.1101/cshperspect.a006502 (opens in a new tab)

  25. 25.

    Song YS, et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer. 2016;122:1370-1379.

    Not in our library10.1002/cncr.29934 (opens in a new tab)

  26. 26.

    Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr. Relat. Cancer. 2016;23:R143-R155.

    Not in our library10.1530/erc-15-0533 (opens in a new tab)

  27. 27.

    Yin DT, et al. Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis. Clin. Endocrinol. 2016;85:299-305.

    Not in our library10.1111/cen.13017 (opens in a new tab)

  28. 28.

    Bell RJ, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015;348:1036-1039.

    Not in our library10.1126/science.aab0015 (opens in a new tab)

  29. 29.

    Davis CF, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26:319-330.

    Not in our library10.1016/j.ccr.2014.07.014 (opens in a new tab)

  30. 30.

    Endo M, et al. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin. Cancer Res. 2011;17:3771-3782.

    Not in our library10.1158/1078-0432.ccr-10-2393 (opens in a new tab)

  31. 31.

    Aesif SW, et al. Loss of p16(INK4A) expression and homozygous CDKN2A deletion are associated with worse outcome and younger age in thymic carcinomas. J. Thorac. Oncol. 2017;12:860-871.

    Not in our library10.1016/j.jtho.2017.01.028 (opens in a new tab)

  32. 32.

    Song YS, et al. Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth. Clin. Cancer Res. 2019;25:414-425.

    Not in our library10.1158/1078-0432.ccr-18-0663 (opens in a new tab)

  33. 33.

    Elvin JA, et al. Clinical benefit in response to palbociclib treatment in refractory uterine leiomyosarcomas with a common CDKN2A alteration. Oncologist. 2017;22:416-421.

    Not in our library10.1634/theoncologist.2016-0310 (opens in a new tab)

  34. 34.

    Konecny GE, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin. Cancer Res. 2011;17:1591-1602.

    Not in our library10.1158/1078-0432.ccr-10-2307 (opens in a new tab)

  35. 35.

    Wiedemeyer WR, et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc. Natl Acad. Sci. USA. 2010;107:11501-11506.

    Not in our library10.1073/pnas.1001613107 (opens in a new tab)

  36. 36.

    Duquette M, et al. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget. 2015;6:42445-42467.

    Not in our library10.18632/oncotarget.6442 (opens in a new tab)

  37. 37.
    Cancer immunotherapy: the beginning of the end of cancer? · 2016
    No notice
  38. 38.

    Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.

    Not in our library10.1126/science.aaa1348 (opens in a new tab)

  39. 39.

    Rizvi H, et al. Molecular determinants of response to anti-Programmed Cell Death (PD)-1 and anti-Programmed Death-Ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J. Clin. Oncol. 2018;36:633-641.

    Not in our library10.1200/jco.2017.75.3384 (opens in a new tab)

  40. 40.

    Chintakuntlawar AV, et al. Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J. Clin. Endocrinol. Metab. 2017;102:1943-1950.

    Not in our library10.1210/jc.2016-3756 (opens in a new tab)

  41. 41.

    Zhang Y, Marin-Acevedo JA, Azzouqa AG, Manochakian R, Lou Y. Association of CDKN2A gene alteration with high expression of PD-L1. J. Clin. Oncol. 2018;36:9102-9102.

    Not in our library10.1200/jco.2018.36.15_suppl.9102 (opens in a new tab)

  42. 42.

    Sterlacci W, Fiegl M, Droeser RA, Tzankov A. Expression of PD-L1 identifies a subgroup of more aggressive non-small cell carcinomas of the lung. Pathobiology. 2016;83:267-275.

    Not in our library10.1159/000444804 (opens in a new tab)

  43. 43.

    Lee DY, et al. Recurrence and survival after gross total removal of resectable undifferentiated or poorly differentiated thyroid carcinoma. Thyroid. 2016;26:1259-1268.

    Not in our library10.1089/thy.2016.0147 (opens in a new tab)

  44. 44.

    Lee DY, et al. Changes of clinicopathologic characteristics and survival outcomes of anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2016;26:404-413.

    Not in our library10.1089/thy.2015.0316 (opens in a new tab)

  45. 45.

    Volante M, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am. J. Surg. Pathol. 2007;31:1256-1264.

    Not in our library10.1097/pas.0b013e3180309e6a (opens in a new tab)

  46. 46.

    DeLellis, R. A., Organització Mundial de la, S, International Agency for Research on C. Pathology and Genetics of Tumours of Endocrine Organs, 3rd edn (IARC Press, 2004).

    Not in our library

  47. 47.

    Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754-1760.

    Not in our library10.1093/bioinformatics/btp324 (opens in a new tab)

  48. 48.

    DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011;43:491-498.

    Not in our library10.1038/ng.806 (opens in a new tab)

  49. 49.
    The landscape of kinase fusions in cancer · 2014
    No notice
  50. 50.

    Costa V, et al. New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma. Oncotarget. 2015;6:11242-11251.

    Not in our library10.18632/oncotarget.3593 (opens in a new tab)

  51. 51.

    Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21.

    Not in our library10.1093/bioinformatics/bts635 (opens in a new tab)

  52. 52.
    HTSeq—a Python framework to work with high-throughput sequencing data · 2014
    No notice
  53. 53.
    Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · 2014
    No notice
  54. 54.

    Liberzon A, et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739-1740.

    Not in our library10.1093/bioinformatics/btr260 (opens in a new tab)

  55. 55.

    Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108-112.

    Not in our library10.1038/nature08460 (opens in a new tab)

  56. 56.

    Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545-15550.

    Not in our library10.1073/pnas.0506580102 (opens in a new tab)

  57. 57.

    Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 2013;31:213-219.

    Not in our library10.1038/nbt.2514 (opens in a new tab)

  58. 58.

    Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.

    Not in our library10.1093/nar/gkq603 (opens in a new tab)

  59. 59.
    Analysis of protein-coding genetic variation in 60,706 humans · 2016
    No notice
  60. 60.

    Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812-3814.

    Not in our library10.1093/nar/gkg509 (opens in a new tab)

  61. 61.

    Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 2013;Chapter 7, Unit 7:20.

    Not in our library10.1002/0471142905.hg0720s76 (opens in a new tab)

  62. 62.

    Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44:e131.

    Not in our library10.1093/nar/gkw520 (opens in a new tab)

  63. 63.

    D’Aurizio R, et al. Enhanced copy number variants detection from whole-exome sequencing data using EXCAVATOR2. Nucleic Acids Res. 2016;44:e154.

    Not in our library10.1093/nar/gkw695 (opens in a new tab)

  64. 64.
    GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers · 2011
    No notice
  65. 65.
    CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing · 2016
    No notice
  66. 66.
    SomaticSignatures: inferring mutational signatures from single-nucleotide variants · 2015
    No notice
  67. 67.

    Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57-74.

    Not in our library10.1038/nature11247 (opens in a new tab)

  68. 68.

    Hnisz D, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155:934-947.

    Not in our library10.1016/j.cell.2013.09.053 (opens in a new tab)

  69. 69.
    Ultrafast and memory-efficient alignment of short DNA sequences to the human genome · 2009
    No notice
  70. 70.
    Model-based Analysis of ChIP-Seq (MACS) · 2008
    No notice
  71. 71.

    Loven J, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320-334.

    Not in our library10.1016/j.cell.2013.03.036 (opens in a new tab)

  72. 72.

    Reyna-Lopez GE, Simpson J, Ruiz-Herrera J. Differences in DNA methylation patterns are detectable during the dimorphic transition of fungi by amplification of restriction polymorphisms. Mol. Gen. Genet. 1997;253:703-710.

    Not in our library10.1007/s004380050374 (opens in a new tab)

Cited by papers we hold 5

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.